Company intelligence / Profile preview
Serilink Biotechnology Company Limited
- Ownership
- Private
- Development stage
- Preclinical
Overview
Serilink has developed a proprietary platform enabling efficient synthesis and modification of complex peptides/proteins as well as the creation of innovative drug conjugates. At least one drug candidate has reached Phase 2 clinical trials. The company also provides plug-and-play kits for small-scale bioconjugate preparation and collaborates with partners to advance programs toward IND stage
- Therapeutic areas
- Other
- Modalities
- Peptide/protein drugsantibody-drug conjugates (ADCs)antibody-radionuclide conjugates (ARCs)peptide-drug conjugates (PDCs)bioconjugation technologies including PEGylation and protein/peptide modification
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Serilink Biotechnology Company Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serilink Biotechnology Company Limited.